 |
|
|
|||||||||
|
Investor RelationsDiaKine Therapeutics, Inc. is a seed-stage company developing therapies addressing type 1 and type 2 diabetes and related complications, with market opportunities exceeding $13 billion. The Company is currently engaged in raising onset bridging capital leading to an A round venture financing. |
||||||||||
|
|
|
|
|
||||||||
|
©2006 DiaKine Therapeutics. All rights reserved.
|
|||||||||||
